AstraZeneca (LSE:AZN) is no longer just a UK pharmaceutical company. With operations in more than 125 countries, a Market Value that vies with Shell and HSBC for the top spot in the FTSE 100, and one of the deepest late-stage drug pipelines in the industry, AZN has become a bellwether for British investors thinking about science-led growth. After a 2025 in which Revenue pushed close to $59 billion and core Earnings-per-share/">Earnings Per Share rose by double digits, attention in 2026 has turned to a busy stream of Phase III readouts, a high-profile push into obesity, and the question of whether AstraZeneca's premium valuation can keep climbing.

This article walks UK investors through what AstraZeneca looks like today: the most recent verified financials, share price context, Dividend policy, the broad shape of the pipeline, and the risks that could shape the stock through the rest of 2026.

Key takeaways

  • AstraZeneca reported FY2025 total revenue of $58.7bn, up 9% at actual rates and 8% at constant exchange rates, according to its full-year results announcement.
  • Core EPS rose 11% to $9.16 for FY2025, with growth across Oncology, CVRM, R&I and Rare Disease.
  • Q1 2026 total revenue came in at $15.3bn, up 8% at constant exchange rates, with core EPS up 5% and core operating profit up 12%.
  • The Board lifted the FY2025 total declared dividend by 3% to $3.20 per share.
  • In April 2026, AstraZeneca closed a strategic collaboration with CSPC Pharmaceuticals for obesity and type 2 diabetes therapies, with a $1.2bn upfront payment.
  • As last reported, AZN's London-listed share price was around 13,534 pence on 18 May 2026, with shares up roughly 22% over the prior 12 months.

Why investors are watching this FTSE 100 stock

Investors are watching AstraZeneca (LSE:AZN) because it has become one of the clearest pure plays on long-term innovation within the FTSE 100. According to the company's own disclosures, AstraZeneca generated roughly $58.7bn of revenue in 2025 and is targeting mid-to-high single-digit revenue growth and low double-digit core EPS growth for 2026. That is a rare combination of scale and growth for a UK-listed Business, and it has underpinned a strong share price performance over the past year.

Beyond the numbers, AstraZeneca has a story that resonates with investors looking for structural themes. Oncology and rare disease drugs have been growing at double-digit rates, the company is pushing aggressively into obesity and weight management, and a string of Phase III readouts in 2026 could refresh the pipeline well into the next decade. For UK shareholders, AZN offers exposure to global healthcare in sterling, with a London listing that keeps it within reach of pensions, ISAs and SIPPs.

Recent share price performance

AstraZeneca's share price has had a strong run into 2026. Market data suggests the stock was around 13,534 pence on 18 May 2026, with another data point during the same period referencing a level as high as 14,412 pence, the highest since December 2025. Over a 12-month window, market data suggests the shares were up around 22%, well ahead of the broader FTSE 100 Index.

What is driving the move

Several factors have supported the share price. Strong FY2025 numbers, in which total revenue rose 9% to $58.7bn and core EPS rose 11% to $9.16, gave the market confidence in delivery. Pipeline news has also been generally positive: AstraZeneca highlighted four successful Phase III readouts in the first half of 2026, including EMERALD-3 with Imfinzi and Imjudo in hepatocellular carcinoma, the OBERON, TITANIA and MIRANDA suite for tozorakimab in COPD, the I CAN study with Ultomiris in IgA nephropathy, and the HICKORY, CHESTNUT and MULBERRY programmes for efzimfotase alfa in hypophosphatasia.

How AZN compares with FTSE 100 peers

AstraZeneca is one of the largest companies in the FTSE 100 by market value. Trailing valuation data from third-party providers has shown AZN's P/E in the high twenties on a current basis, with a forward P/E based on 2026 estimates closer to 18. That puts AZN on a clear premium to many FTSE 100 stocks, but in line with global big-pharma peers that combine size with above-average growth.

Business performance and earnings

AstraZeneca's FY2025 results, released in early 2026, were defined by broad-based growth. Total revenue increased by 9% to $58.7bn, with growth at constant exchange rates of 8%. Q4 2025 revenue grew by 4% to $15.5bn. Core earnings per share rose 11% to $9.16. The full-year report highlighted strength across all four therapy areas: Oncology, CardioVascular, Renal and Metabolism (CVRM), Respiratory and Immunology (R&I), and Rare Disease.

The composition of growth matters. Oncology continued to be the largest contributor, with multiple existing brands growing and a deepening pipeline of new molecular entities. Rare Disease, which AstraZeneca built out via its Acquisition of Alexion, has continued to grow at double-digit rates. CVRM benefited from continued momentum behind diabetes and heart-failure franchises, and R&I has been bolstered by new launches and label extensions.

Q1 2026: a solid start

AstraZeneca's Q1 2026 results, released in late April, showed total revenue of $15.3bn, up 8% at constant exchange rates. Core EPS rose 5% and core operating profit was up 12%, supported by stronger gross margins and ongoing Operating Leverage. Management reaffirmed its FY2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, citing a 21% core tax rate and improving operating margins.

Pipeline news was also a feature of the quarter. The company emphasised that it is in a catalyst-rich phase, with positive data from four high-value Phase III programmes since the previous quarterly results and the first pivotal data for two key new molecular entities, including tozorakimab in COPD and efzimfotase alfa in hypophosphatasia. Investors viewed the results as a confirmation that AstraZeneca can continue to grow earnings even as it invests heavily in R&D.

Dividends and Shareholder returns

AstraZeneca is not the highest yielding stock in the FTSE 100, but it has a consistent, progressive dividend policy. According to the FY2025 results, the Board approved a 3% increase in the total declared dividend for the year to $3.20 per share. Third-party dividend data aggregators show a trailing Yield around 1.6% and a forward yield closer to 2.2%, depending on the data source and date.

Dividends are typically paid twice a year, with currency conversion implications for UK shareholders who receive sterling payments from a US dollar-denominated declaration. The dividend has grown at an average rate of around 9.8% per year over the past three years, according to one third-party data provider. AstraZeneca has historically prioritised reinvestment in R&D and selective bolt-on transactions over outsized share Buybacks, which differentiates it from some FTSE 100 cash-return stories.

Valuation and market position

AstraZeneca is among the largest companies in the FTSE 100 by Market Capitalisation, and as last reported was one of the most valuable listed pharmaceutical groups in Europe. The premium valuation reflects a combination of factors: scale, double-digit growth across oncology and rare disease, a deep mid- and late-stage pipeline, and a credible long-term revenue ambition out to 2030.

On valuation metrics, third-party data providers show AstraZeneca's trailing P/E in the high twenties and forward P/E closer to 18 based on 2026 earnings estimates. Compared with global pharma peers such as Eli Lilly, Novartis, Roche or GSK, AstraZeneca tends to trade somewhere in between on multiples, with investors typically willing to pay up for growth and pipeline visibility. UK investors comparing AZN with GSK should remember that the two have made very different strategic choices over the past decade, with AstraZeneca taking a larger oncology bet and now leaning into obesity.

The benchmark for valuation will continue to be delivery. Management has guided to mid-to-high single-digit revenue growth in 2026 and to low double-digit core EPS growth, alongside ambitions to deliver more than 20 new medicines by 2030. Meeting those targets will be central to whether the current premium can be sustained.

Sector trends shaping AstraZeneca

Several trends are shaping AstraZeneca and the wider pharmaceutical sector. The first is the rise of Biologics and targeted therapies in oncology. AstraZeneca has been one of the most prolific developers in this space, with antibody drug conjugates, immune checkpoint inhibitors and combination regimens at the centre of its growth story. Recent regulatory milestones, including a Priority Review for Datroway in triple negative breast cancer and a positive EU opinion for Imfinzi in gastric and gastroesophageal junction cancers, underline the breadth of its oncology portfolio.

The second is obesity and cardiometabolic disease. The class of GLP-1 receptor agonists has reshaped competitive dynamics across the industry. AstraZeneca's weight management portfolio includes elecoglipron, formerly AZD5004, an oral GLP-1 receptor agonist licensed from Eccogene; AZD6234, a weekly injectable selective amylin receptor agonist; and AZD9550, a weekly injectable dual GLP-1 and glucagon receptor agonist. The April 2026 collaboration with CSPC Pharmaceuticals added eight further programmes via a strategic deal with a $1.2bn upfront payment.

The third is rare disease, where AstraZeneca's Alexion-led Franchise continues to grow. The fourth is geographic mix. Emerging markets and China remain large contributors to growth but also bring foreign exchange and policy risk. Finally, the broader policy environment is a key theme. Drug pricing reform in the United States, the operation of the Inflation Reduction Act, and UK and EU access negotiations could all weigh on industry margins, even as innovation pipelines expand.

Risks to watch

AstraZeneca carries a familiar list of risks for a large global pharma. Clinical trial outcomes remain the most consequential. Even with a deep pipeline, a high-profile failure in a late-stage programme can wipe out billions in expected sales. Investors should be wary of single-readout outcomes that move the share price sharply in either direction.

Patent expirations are another important Factor. While AstraZeneca has been re-shaping its product portfolio to reduce reliance on older patents, future loss-of-exclusivity events in mature franchises could weigh on revenue and earnings. The shift to biologics offers some protection, but generic and biosimilar competition is a constant feature of the sector.

Pricing and policy risk is a third area. US drug pricing reform under the Inflation Reduction Act continues to evolve, and similar conversations are taking place in European markets. Currency is also relevant for UK shareholders: AstraZeneca reports in US dollars but is listed in sterling, so the value of dividends and reported earnings can shift with the GBP/USD rate.

Execution on M&A and partnerships is a further risk. The CSPC deal underscores AstraZeneca's willingness to back its convictions with cash, but the eventual return on these investments depends on clinical and commercial outcomes. Finally, AstraZeneca is sensitive to broader Equity-market sentiment. Premium-valued Growth Stocks can de-rate quickly during macro shocks, even when underlying fundamentals remain intact.